BIO-TECHNE Corp vs Western Digital Corp — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Western Digital Corp trades at $399 (market cap $151.76B). The key difference: Western Digital Corp is far larger — about 13.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Western Digital Corp for 37 Days on average.
| TECH | WDC | |
|---|---|---|
Market Cap | $11.37B | $151.76B |
Volume | 3,153,511 | 7,162,789 |
Sector | Health | Technology |
52-Week High | $72.61 | $746.23 |
52-Week Low | $43.31 | $113.13 |
Typical Hold Time | 63 Days | 37 Days |
Enterprise Value | $11.40B | $151.23B |
Dividend Yield | 0.44% | 0.15% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Western Digital (WDC) trades at $393.31, down 4.31% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with a P/E of 15.06 and impressive profitability metrics including 131.02% ROE and 71.97% net income margin. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $3.56 exceeding the $3.31 estimate. Technical indicators show bearish momentum with the price testing key support levels around $391-$400.
Despite near-term competitive pressures, Western Digital maintains strong analyst support with 72% buy ratings and a $647.58 consensus price target representing 65% upside. The company's dominant 40%+ market share in HDDs and AI-driven storage demand provide long-term growth catalysts, though investors should monitor Toshiba's capacity expansion impact on pricing power and margins in the competitive storage market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →